Ganciclovir Treatment of Serious Cytomegalovirus Infection in Heart and Heart-Lung Transplant Recipients

Keay, Susan; Petersen, Eskild A.; Icenogle, Timothy B.; Zeluff, Barry; Samo, Tobias; Busch, David F.; Newman, Cheryl; Buhles, William; Merigan, Thomas C.

doi:10.1093/clinids/10.supplement_3.s563

Cited by 51 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravenous ganciclovir has been successfully used in uncontrolled, nonrandomized therapeutic trials to treat solid-organ transplant recipients with CMV disease (52,59,77,83,88,90,106,116,185,186,192,207,212,217,226,254,275,281,296,322,324,325,339,386,397,428,430,446,451,490,496). To date, intravenous ganciclovir remains the drug of choice for the treatment of CMV disease.…”

Section: Ganciclovirmentioning

confidence: 99%

New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients

Sia¹,

Patel²

2000

Clinical Microbiology Reviews

220

181

View full text Add to dashboard Cite

Section: Ganciclovirmentioning

confidence: 99%

New Strategies for Prevention and Therapy of Cytomegalovirus Infection and Disease in Solid-Organ Transplant Recipients

Sia¹,

Patel²

2000

Clinical Microbiology Reviews

220

181

View full text Add to dashboard Cite

“…Cytokines had no apparent role in the pathogen esis of HCMV pneumonitis after BMT [150], and pro found differences have been described between the cellu lar immune response to HCMV as compared to the murine model [18]. Significant effects of antiviral treat ment of pneumonitis in solid organ transplant recipients and BMT recipients have been reported in recent years [151][152][153][154][155][156]. On the other hand, as predicted by the immunopathology hypothesis, prophylactic antiviral treatment and preemptive antiviral therapy have been more effi cient in preventing mortality from HCMV-associated pneumonitis than treatment of manifest disease [157][158][159].…”

Section: Direct Cytopathogenicitymentioning

confidence: 99%

Human Cytomegalovirus Cell Tropism and Pathogenesis

Sinzger¹,

Jahn²

1996

Intervirology

179

178

View full text Add to dashboard Cite

The human cytomegalovirus (HCMV) can cause lifelong infection with episodes of endogenous reactivation. Intrauterine fetal infection and infection of immunocompromised patients are well known to result in significant morbidity. Studies on HCMV cell tropism in vivo revealed three characteristics: (1) ubiquitously distributed cell types such as epithelial cells, endothelial cells and fibroblasts are the major targets of HCMV infection; (2) leukocytes circulating in the peripheral blood are susceptible to the virus, and (3) specialized parenchymal cells such as smooth muscle cells in the gastrointestinal tract and hepatocytes can also be infected. Questions to be resolved are, how the virus spreads throughout the organism, how it can impair the function of infected organs, and how it evades the host’s immune response to establish lifelong infection. This chapter is focused on the role of HCMV-infected target cells for the pathogenesis of HCMV-associated disease in the acutely infected immunocompromised host.

show abstract

“…Ganciclovir (Cymevan | is commonly used in transplant patients for treatment of cytomegalovirus (CMV) diseases or prophylaxis [1]. In spite of dramatic improvements during the last years, multi-organ failure could occur after transplantation and is frequently managed by ultrafiltration or continuous technics of dialysis.…”

Section: Kinetics -Cvvhdmentioning

confidence: 99%